

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer

E Sun Paik^{1,*}, Tae-Hyun Kim^{2,*}, Young Jae Cho^{3,*}, Jiyeon Ryu³, Jung-Joo Choi³, Yoo-Young Lee³, Tae-Joong Kim³, Chel-Hun Choi³, Woo Young Kim¹, Jason K. Sa⁴, Jin-Ku Lee⁵, Byoung-Gie Kim³, Duk-Soo Bae³, Hee Dong Han⁶, Hyung Jun Ahn⁷, Jeong-Won Lee^{3,8,9, **}

¹Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

²Department of Obstetrics and Gynecology, Konyang University Hospital, Daejeon, Republic of Korea

³Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁴Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea

⁵Department of Biochemistry & Molecular Biology, Ajou University, School of Medicine, Suwon, Republic of Korea

⁶Department of Immunology, School of Medicine, Konkuk University, Chungju, Republic of Korea

⁷Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea

⁸Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.

⁹Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

*These authors contributed equally to this work.

****Corresponding Author:**

Jeong-Won Lee, MD, PhD

Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University
School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. Tel.: +82-2-3410-1382; Fax:
+82-2-3410-0630. E-mail address: garden.lee@samsung.com (J.-W. Lee)

Supplementary file 1. Invasion assay-MMP2/MMP9 ELISA in HeyA8 and HeyA8-MDR.

Supplementary file 2. Full-length gels and blots for figure 3C (HeyA8).

Supplementary file 3. Full-length gels and blots for figure 3D (HeyA8-MDR).